Camp4 Therapeutics Corp

Camp4 Therapeutics Corporation announced it granted non-qualified stock options to purchase an aggregate of 39,000 shares of its common stock to three newly hired employees on June 15, 2026. These inducement grants, made in accordance with Nasdaq Listing Rule 5635(c)(4), have an exercise price of $3.96 per share, matching the closing price on the grant date. The options will vest over a four-year period, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, contingent on continued employment.

Camp4 Therapeutics' stockholders approved an amendment to the 2024 Equity Incentive Plan, modifying the evergreen provision to include pre-funded warrants in the calculation of the annual share increase. Concurrently, the Board adopted a new 2026 Inducement Plan, authorizing up to 500,000 shares for various stock-based awards to attract and retain employees, without requiring stockholder approval per Nasdaq rules. Additionally, at the Annual Meeting, stockholders elected three Class II directors and ratified Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2026.

CAMP4 Therapeutics announced new preclinical data for CMP-002, its lead investigational therapeutic candidate for SYNGAP1-related disorder (SRD). The data, presented at the TIDES conference, showed statistically significant improvements in seizure threshold and severity in a SYNGAP1 haploinsufficient mouse model. These findings build upon prior preclinical evidence of neurodevelopmental benefits, suggesting CMP-002 has the potential for broad therapeutic impact by restoring SYNGAP1 protein levels. The company plans to initiate a Phase 1/2 clinical trial for CMP-002 in SRD patients in the second half of 2026.

Camp4 Therapeutics announced new preclinical data for CMP-002, its lead therapeutic candidate for SYNGAP1-related disorder (SRD). The data, presented at the TIDES conference, showed that CMP-002 administration led to a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model. This builds on previous findings of neurodevelopmental benefits, suggesting a broad therapeutic impact by restoring SYNGAP1 protein levels. The company plans to advance CMP-002 into a Phase 1/2 clinical trial for SRD in the second half of 2026.

Camp4 Therapeutics reported an increased net loss for Q1 2026, reaching $18.3 million, compared to $12.4 million in Q1 2025. Research and collaboration revenue grew by 50.8% to $1.29 million. The company's cash and cash equivalents stood at $99.2 million as of March 31, 2026, and it expects to fund operations for at least 12 months. The derivative tranche liability increased by $6.19 million, contributing to the higher net loss, and two collaboration agreements with Fulcrum and BioMarin terminated.

CAMP4 Therapeutics reported a net loss of $18.3 million for the first quarter ended March 31, 2026, an increase from $12.4 million in the prior year. The company announced significant clinical progress, including the submission of its first regulatory filing for CMP-002 in Australia and receiving Orphan Designation from the European Medicines Agency. CAMP4 expects to initiate a global Phase 1/2 clinical trial for CMP-002 in SYNGAP1 patients in the second half of 2026 and projects its cash runway into 2028 with $99.2 million in cash and cash equivalents.

Camp4 Therapeutics announced significant progress in its clinical development, including the submission of its first regulatory filing for CMP-002 in Australia, with plans to initiate a global Phase 1/2 clinical trial in SYNGAP1 patients in the second half of 2026. The company also received Orphan Designation for CMP-002 from the European Medicines Agency and entered a collaboration with CURE SYNGAP1. Financially, Camp4 reported $99.2 million in cash and cash equivalents as of March 31, 2026, with a cash runway expected into 2028, though its net loss for Q1 2026 increased to $18.3 million.

CAMP4 Therapeutics Corp granted non-qualified stock options for an aggregate of 43,000 shares of its common stock to three newly hired employees. These inducement grants, made on April 15, 2026, have an exercise price of $4.59 per share, matching the closing price on the grant date. The options will vest over a four-year period, with 25% vesting after one year and the remainder in monthly installments, subject to continued employment.